VAN-ZOLMITRIPTAN TABLET
Država: Kanada
Jezik: angleščina
Source: Health Canada
Lastnosti izdelka
(SPC)
09-04-2015
Nekateri dokumenti za ta izdelek trenutno niso na voljo, pošljete lahko zahtevo v našo stranko in obvestili vas bomo takoj, ko jih bomo lahko pridobili.
Pošlji zahtevo.
Pošlji zahtevo.
Aktivna sestavina:
ZOLMITRIPTAN
Dostopno od:
VANC PHARMACEUTICALS INC
Koda artikla:
N02CC03
INN (mednarodno ime):
ZOLMITRIPTAN
Odmerek:
2.5MG
Farmacevtska oblika:
TABLET
Sestava:
ZOLMITRIPTAN 2.5MG
Pot uporabe:
ORAL
Enote v paketu:
100
Tip zastaranja:
Prescription
Terapevtsko območje:
SELECTIVE SEROTONIN AGONISTS
Povzetek izdelek:
Active ingredient group (AIG) number: 0134381001; AHFS:
Status dovoljenje:
CANCELLED PRE MARKET
Datum dovoljenje:
2019-07-31
Lastnosti izdelka
Page | 1
PRODUCT MONOGRAPH
PR
VAN-ZOLMITRIPTAN
ZOLMITRIPTAN TABLETS
2.5 MG
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
MANUFACTURER AND DISTRIBUTOR:
Vanc Pharmaceuticals Inc.
Date of Preparation: March 25, 2015
Unit-210, 2639 Viking Way
Richmond, BC V6V 3B7
www.vancpharm.com
Control# 182335
Page | 2
TABLE OF CONTENTS
PRODUCT MONOGRAPH
......................................................................................................
1
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
5
ADVERSE REACTIONS
....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
17
DOSAGE AND ADMINISTRATION
................................................................................
19
OVERDOSAGE
..................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 20
STORAGE AND STABILITY
............................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 23
PART II: SCIENTIFIC INFORMATION
...............................................................................
24
PHARMACEUTICAL INFORMATIO
Preberite celoten dokument
